Innovative NeurovaScular Product surveIllance REgistry (INSPIRE)
The purpose of this study is to collect information over time about how the approved Pipeline™ Shield Device is working and/or the outcome of the treatment. The study will be used to support post-market surveillance activities and post-approval studies (e.g., to collect safety and performance information). In addition, it will be used to obtain clinical evidence for the development and improvement of medical devices, therapies, device guidelines, patient services/solutions and provide clinical data to support health economics and clinical outcomes research. The Pipeline™ Shield Device is not investigational and the procedures being performed are not experimental. The study sponsor is Micro Therapeutics, Inc. d/b/a ev3 Neurovascular (a wholly owned subsidiary of Medtronic/Medtronic, Inc. (“Medtronic”). This product has been approved or cleared by the U.S. Food and Drug Administration (FDA) and is available on the market for use in patients who have a brain aneurysm similar to yours. The Pipeline™ Shield Device is a cylindrical metal mesh that is implanted into the blood vessel across the opening (or ‘neck’) of your brain aneurysm to slow down or stop the blood flow into the aneurysm, causing the blood within the aneurysm to clot. This can help prevent the aneurysm from getting bigger and makes it less likely for the aneurysm to rupture. The Pipeline™ Shield Device also has a surface modification (Shield Technology™) that is chemically bonded to the strands of the device to reduce the likelihood of producing a blood clot when the device is in contact with blood.
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2)
The purpose of the study is to evaluate the biological activity of systemic therapies in people with Neurofibromatosis type 2 (NF2) related tumors. Tumor types eligible for inclusion upon progression will include vestibular schwannomas (VS), non-vestibular schwannomas (non-VS), meningiomas, and ependymomas. We want to assess safety and tolerability of Brigatinib to determine how subjects respond to the study agent. The study drug Brigatinib is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.
Inpatient Pediatric Hospitalist Service | NYU Langone Health
Pediatric hospitalists, who are inpatient specialists, care for children at Hassenfeld Children’s Hospital at NYU Langone.
Inpatient Psychiatry at Tisch Hospital | NYU Langone Health
Voluntary inpatient psychiatric care from our highly trained psychiatrists and therapists is available at NYU Langone’s Tisch Hospital.
Inpatient Psychiatry at Tisch Hospital Doctors | NYU Langone Health
Find a doctor at the Inpatient Psychiatry at Tisch Hospital at NYU Langone.
Inpatient Treatment for Glomerulonephritis in Children | NYU Langone Health
Specialists at Hassenfeld Children’s Hospital at NYU Langone offer various in-hospital treatments for children with severe glomerulonephritis.
Insomnia and its association with myasthenia gravis and peripheral neuropathy
The purpose of the study is to: Better understand how sleep affects quality of life and fatigue in people with myasthenia gravis (MG). Better understand how sleep affects quality of life and neuropathic pain in people with peripheral neuropathy. Better understand what people are using to manage their conditions (i.e. sleep, neuropathy, and myasthenia gravis. Integrative therapy refers to what types of vitamins, supplements, exercises, meditation or apps on your phone are being used to help to manage neuropathy, myasthenia gravis, or sleep-related issues. Sleep patterns can be changed and better management of sleep may 1) improve neuropathic pain perception and quality of life related to pain in people with peripheral neuropathy, and 2) improve perceptions of fatigue and quality of life in people with myasthenia gravis.
Insurance, Billing & Financial Assistance | NYU Langone Health
Find out more about insurance coverage, billing, and financial assistance at NYU Langone Health.
Integrated multi-omics approaches to precision medicine in kidney disease (iMAP-Kidney)
The primary objective of the study is to establish a biorepository (tissue bank) for the storage of genetic material (DNA), blood cell RNA, plasma, serum, urine, and fresh tissue from patients undergoing kidney biopsy. This objective will be accomplished through the following: 1) establishing a clinical registry containing information related to the patient’s ethnicity, race, gender, age, medications, specific disease or state of health; 2) digitizing kidney histology slides from kidney tissue biopsies for artificial-intelligence-based evaluation or pathologist-based scoring; and 3) allowing for accessibility to newly obtained samples for ongoing related studies patients with kidney disease.
Integrating Financial Coaching and Smoking Cessation Coaching
The purpose of this research study is to test a program that combines financial coaching with quit smoking coaching and nicotine replacement therapy (nicotine gum, lozenges or patches). As researchers, we are interested in how these two types of coaching can affect participants’ stress, wellness, and ability to quit smoking cigarettes. Learning about it will help us improve the program for patients and staff.